Please check your internet connection and try again.
# Ticagrelor (Brilinta)
## Overview
Ticagrelor is a direct-acting, reversibly binding P2Y12 platelet inhibitor. It is used to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
## Primary Indications
* **Acute Coronary Syndrome (ACS):** To reduce the rate of thrombotic cardiovascular events (e.g., cardiovascular death, myocardial infarction, stroke) in patients with a history of ACS. Typically used in combination with aspirin.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for at least 12 months, or longer if tolerated and indicated.
* **If prior treatment with a P2Y12 inhibitor:** Consider interruption of prior P2Y12 inhibitor treatment before initiating ticagrelor.
* **Secondary Prevention (Post-MI/Stroke):** For patients with a history of myocardial infarction (MI) who are at high risk of further occlusive events, ticagrelor 60 mg orally twice daily may be considered after the initial 12 months of treatment with 90 mg twice daily.
## Pediatric Dosing
* There is no established pediatric dosing for ticagrelor.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is required for mild to moderate renal impairment. In severe renal impairment, use with caution.
* **Hepatic Impairment:** No dose adjustment is required for mild to moderate hepatic impairment. Avoid use in severe hepatic impairment.
## Contraindications
* Active pathological bleeding.
* History of transient ischemic attack (TIA) or stroke (when used as part of ACS treatment, unless part of a specific clinical trial or local protocol).
* Hypersensitivity to ticagrelor or any of its excipients.
## Adverse Effects
* **Common:** Bleeding (major and minor), dyspnea, bradycardia, ventricular pauses.
* **Serious:** Severe bleeding, life-threatening bleeding, anaphylaxis.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase ticagrelor exposure. Co-administration with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) can decrease ticagrelor exposure.
* **Aspirin:** Co-administration with aspirin is generally recommended for ACS, but the risk of bleeding is increased.
* **Other Antithrombotics:** Concomitant use with other drugs affecting hemostasis (e.g., anticoagulants, other antiplatelets, NSAIDs) increases the risk of bleeding.
* **CYP2C19 Substrates:** Ticagrelor is an inhibitor of CYP2C19. Avoid co-administration with clopidogrel (unless specific indication or local protocol dictates) and other CYP2C19 substrates if possible, or use with caution.
## Monitoring
* **Bleeding:** Monitor for signs and symptoms of bleeding, especially in patients with increased risk factors.
* **Heart Rate:** Ticagrelor can cause asymptomatic bradycardia; monitor for symptoms of bradycardia if clinically indicated.
* **Renal and Hepatic Function:** Periodic assessment may be warranted, especially in patients with pre-existing impairment.
## Clinical Pearls
* Ticagrelor is a P2Y12 inhibitor, not a thienopyridine, and does not require metabolic activation.
* The reversibility of ticagrelor's action may be beneficial in patients requiring urgent surgery.
* Dyspnea is a common side effect and may not be cardiac in origin. It often resolves with continued therapy.
* Ticagrelor's efficacy is established in combination with aspirin. The duration of dual antiplatelet therapy (DAPT) depends on individual patient risk factors for ischemic events versus bleeding.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and institutional protocols for definitive guidance.
